Trial Profile
An Open Label, Randomized, Parallel Group, Prospective, Multicenter Clinical Trial for Evaluation of Efficacy and Safety of IN-ALRN-001 in Comparison with Tamsulosin in Patients with lower urinary tract symptoms associated with BPH.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Sep 2016
Price :
$35
*
At a glance
- Drugs IN ALRN 001 (Primary) ; Tamsulosin
- Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
- Focus Registrational; Therapeutic Use
- Sponsors Intas Pharmaceuticals
- 09 Feb 2010 New trial record